Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CD34 POSITIVE PBPC EXPANDED EX-VIVO MAY NOT PROVIDE DURABLE ENGRAFTMENT FOLLOWING MYELOABLATIVE CHEMORADIOTHERAPY REGIMENS
Autore:
HOLYOAKE TL; ALCORN MJ; RICHMOND L; FARRELL E; PEARSON C; GREEN R; DUNLOP DJ; FITZSIMONS E; PRAGNELL IB; FRANKLIN IM;
Indirizzi:
GLASGOW ROYAL INFIRM,DEPT HAEMATOL,84 CASTLE ST GLASGOW G4 0SF LANARKSCOTLAND GLASGOW ROYAL INFIRM,DEPT HAEMATOL GLASGOW G4 0SF LANARK SCOTLAND GLASGOW ROYAL INFIRM,DEPT MED ONCOL GLASGOW G4 0SF LANARK SCOTLAND W SCOTLAND BLOOD TRANSFUS SERV CARLUKE LANARK SCOTLAND MONKLANDS HOSP,DEPT HAEMATOL AIRDRIE SCOTLAND BEATSON INST CANC RES GLASGOW G61 1BD LANARK SCOTLAND
Titolo Testata:
Bone marrow transplantation
fascicolo: 11, volume: 19, anno: 1997,
pagine: 1095 - 1101
SICI:
0268-3369(1997)19:11<1095:CPPEEM>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
BONE-MARROW TRANSPLANTATION; HIGH-DOSE CHEMOTHERAPY; PROGENITOR CELLS; EXVIVO EXPANSION;
Keywords:
EX VIVO EXPANSION; CD34 POSITIVE; PBPC; MYELOABLATIVE CHEMORADIOTHERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
18
Recensione:
Indirizzi per estratti:
Citazione:
T.L. Holyoake et al., "CD34 POSITIVE PBPC EXPANDED EX-VIVO MAY NOT PROVIDE DURABLE ENGRAFTMENT FOLLOWING MYELOABLATIVE CHEMORADIOTHERAPY REGIMENS", Bone marrow transplantation, 19(11), 1997, pp. 1095-1101

Abstract

We have previously demonstrated that CD34(+) cells, selected from peripheral blood progenitor cells (PBPC), can be expanded in ex vivo culture and can be infused in tandem with unmanipulated PBPC with little or no toxicity, In this study, four patients (two non-Hodgkin's lymphoma (NHL), two multiple myeloma (MM)) received myeloablative conditioning prior to stem cell rescue using ex vivo expanded cells alone, The two patients with NHL received cyclophosphamide and total body irradiation (CY/TBI) and the two patients with MM, busulphan and melphalan (Bu/M), One case received an inadequate CFU-GM dose, despite expansion, and in one case the expanded cells were contaminated, No definitive conclusions may therefore be drawn concerning engraftment in these two cases. However, the other two cases received high doses of committed progenitors, Following infusion of the expanded material, all four patients failed to show sustained neutrophil engraftment and none showed evidence of platelet engraftment, Back-up, unmanipulated PBPC were therefore infused on days 14, 34, 32 and 28 and subsequently all four cases achieved satisfactory engraftment of both neutrophils and platelets, Inconclusion, we feel that, CD34(+) cells, expanded ex vivo using the conditions described in this report, may not provide durable engraftment following fully myeloablative conditioning.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/09/20 alle ore 08:30:00